What is HC Wainwright’s Estimate for ONCY Q1 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Oncolytics Biotech in a report released on Wednesday, October 29th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.07) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.06) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06.

Other equities research analysts have also issued reports about the company. Wall Street Zen upgraded Oncolytics Biotech from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Lake Street Capital assumed coverage on Oncolytics Biotech in a research note on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Oncolytics Biotech Trading Up 2.6%

ONCY stock opened at $1.19 on Friday. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.51. The firm has a market cap of $119.43 million, a P/E ratio of -4.41 and a beta of 1.24. The business’s 50 day moving average is $1.23 and its 200-day moving average is $0.91.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently raised its position in Oncolytics Biotech stock. Seeds Investor LLC increased its holdings in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) by 17.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,767 shares of the company’s stock after acquiring an additional 33,826 shares during the period. Seeds Investor LLC owned about 0.23% of Oncolytics Biotech worth $173,000 at the end of the most recent quarter. 6.82% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.